Clinical Trial Update: A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. [Phase 1]

View source ↗

Summary

This clinical trial update outlines a Phase 1 study of HWK-016, a MUC16-directed antibody-drug conjugate, in participants with advanced solid tumors, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• HWK-016 (MUC16-directed antibody-drug conjugate)

Snippet

Sponsor: Whitehawk Therapeutics, Inc. | Conditions: PROC, Platinum Resistant Ovarian Cancer | Phase 1 | Status: RECRUITING